Upregulation of MYBL2 independently predicts a poorer prognosis in patients with clear cell renal cell carcinoma

Sun,Shan‑Shan; Fu,Yang; Lin,Jian‑Yang

doi:10.3892/ol.2020.11408

Upregulation of MYBL2 independently predicts a poorer prognosis in patients with clear cell renal cell carcinoma

Authors:
- Shan‑Shan Sun
- Yang Fu
- Jian‑Yang Lin
View Affiliations

Affiliations: Department of Pharmacy, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Urology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China
Published online on: February 17, 2020 https://doi.org/10.3892/ol.2020.11408
Pages: 2765-2772
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MYB protooncogene‑like 2 (MYBL2) is a transcription factor that is upregulated and significantly associated with various human cancer types. However, the potential role of MYBL2 in clear cell renal cell carcinoma (ccRCC) is yet to be elucidated. Therefore, the expression and biological functions of MYBL2 in ccRCC were assessed in the current study using The Cancer Genome Atlas (TCGA). A Wilcoxon signed‑rank test was performed to compare MYBL2 expression between ccRCC and normal tissues. Moreover, the association between MYBL2 expression and various clinicopathological factors was estimated using both the Wilcoxon signed‑rank test and logistic regression. The differences in prognosis between patients with high‑ and low‑MYBL2 expression were analyzed via the Kaplan‑Meier method and Cox regression analysis. Finally, gene set enrichment analysis (GSEA) was performed to investigate the biofunctions of MYBL2 in ccRCC. It was revealed that MYBL2 was upregulated in ccRCC, and that the MYBL2 high‑expression phenotype was significantly associated with sex, a high histological grade, an advanced clinical stage, tumor stage, lymph node metastasis, distant metastasis and poor overall survival (OS). It was also revealed, via the Cox regression analysis, that the upregulation of MYBL2 expression was able to independently predict a poor prognosis in patients with ccRCC. GSEA indicated that the intestinal immune network for IgA production, primary immunodeficiency, the janus kinase (JAK)‑signal transducer and activator of transcription (STAT) signaling pathway, the cytosolic DNA‑sensing pathway, the p53 signaling pathway and the chemokine signaling pathway were all enriched in the high‑MYBL2 expression datasets. In conclusion, the present findings indicate that MYBL2 may be used as an independent prognostic factor in patients with ccRCC.

View Figures

View References

1	Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O and Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 103:356–387. 2018. View Article : Google Scholar : PubMed/NCBI
2	Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernández-Pello S, Giles RH, Hofmann F, Hora M, Kuczyk MA, et al: European association of urology guidelines on renal cell carcinoma: The 2019 update. Eur Urol. 75:799–810. 2019. View Article : Google Scholar : PubMed/NCBI
3	Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, et al: Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 15:804–834. 2017. View Article : Google Scholar : PubMed/NCBI
4	Gore ME and Larkin JM: Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer. 104:399–406. 2011. View Article : Google Scholar : PubMed/NCBI
5	Iness AN, Felthousen J, Ananthapadmanabhan V, Sesay F, Saini S, Guiley KZ, Rubin SM, Dozmorov M and Litovchick L: The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb. Oncogene. 38:1080–1092. 2019. View Article : Google Scholar : PubMed/NCBI
6	Jia Y, Gao Y, Li J, Chang Z, Yan J and Qin Y: Prognostic implications of MYBL2 in resected Chinese gastric adenocarcinoma patients. Onco Targets Ther. 12:1129–1135. 2019. View Article : Google Scholar : PubMed/NCBI
7	Chen J and Chen X: MYBL2 is targeted by miR-143-3p and regulates breast cancer cell proliferation and apoptosis. Oncol Res. 26:913–922. 2018. View Article : Google Scholar : PubMed/NCBI
8	Qin H, Li Y, Zhang H, Wang F, He H, Bai X and Li S: Prognostic implications and oncogenic roles of MYBL2 protein expression in esophageal squamous-cell carcinoma. Onco Targets Ther. 12:1917–1927. 2019. View Article : Google Scholar : PubMed/NCBI
9	Guan Z, Cheng W, Huang D and Wei A: High MYBL2 expression and transcription regulatory activity is associated with poor overall survival in patients with hepatocellular carcinoma. Curr Res Transl Med. 66:27–32. 2018. View Article : Google Scholar : PubMed/NCBI
10	Jin Y, Zhu H, Cai W, Fan X, Wang Y, Niu Y, Song F and Bu Y: B-Myb is up-regulated and promotes cell growth and motility in non-small cell lung cancer. Int J Mol Sci. 18(pii): E8602017. View Article : Google Scholar : PubMed/NCBI
11	Yu R, Li C, Lin X, Chen Q, Li J, Song L, Lin L, Liu J, Zhang Y, Kong W, et al: Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma. Pathol Res Pract. 213:964–968. 2017. View Article : Google Scholar : PubMed/NCBI
12	Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, et al: AJCC Cancer Staging Manual. 8th. Springer; pp. 751–752. 2017
13	Wu H and Zhang J: Decreased expression of TFAP2B in endometrial cancer predicts poor prognosis: A study based on TCGA data. Gynecol Oncol. 149:592–597. 2018. View Article : Google Scholar : PubMed/NCBI
14	Team RC: R: A language and environment for statistical computing. R foundation for statistical computing, version 2.15.1; Vienna, Austria: 2012
15	Musa J, Aynaud MM, Mirabeau O, Delattre O and Grünewald TG: MYBL2 (B-Myb): A central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis. Cell Death Dis. 8:e28952017. View Article : Google Scholar : PubMed/NCBI
16	Fan X, Wang Y, Jiang T, Cai W, Jin Y, Niu Y, Zhu H and Bu Y: B-Myb mediates proliferation and migration of non-small-cell lung cancer via suppressing IGFBP3. Int J Mol Sci. 19(pii): E14792018. View Article : Google Scholar : PubMed/NCBI
17	Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
18	Khatri P, Sirota M and Butte AJ: Ten years of pathway analysis: Current approaches and outstanding challenges. PLoS Comput Biol. 8:e10023752012. View Article : Google Scholar : PubMed/NCBI
19	Yang Z, Tao Y, Xu X, Cai F, Yu Y and Ma L: Bufalin inhibits cell proliferation and migration of hepatocellular carcinoma cells via APOBEC3F induced intestinal immune network for IgA production signaling pathway. Biochem Biophys Res Commun. 503:2124–2131. 2018. View Article : Google Scholar : PubMed/NCBI
20	Mayor PC, Eng KH, Singel KL, Abrams SI, Odunsi K, Moysich KB, Fuleihan R, Garabedian E, Lugar P, Ochs HD, et al: Cancer in primary immunodeficiency diseases: Cancer incidence in the United States immune deficiency network registry. J Allergy Clin Immunol. 141:1028–1035. 2018. View Article : Google Scholar : PubMed/NCBI
21	Villarino AV, Kanno Y and O'Shea JJ: Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 18:374–384. 2017. View Article : Google Scholar : PubMed/NCBI
22	Cui C, Cheng X, Yan L, Ding H, Guan X, Zhang W, Tian X and Hao C: Downregulation of TfR1 promotes progression of colorectal cancer via the JAK/STAT pathway. Cancer Manag Res. 11:6323–6341. 2019. View Article : Google Scholar : PubMed/NCBI
23	Toh TB, Lim JJ, Hooi L, Rashid MBMA and Chow EK: Targeting Jak/Stat pathway as a therapeutic strategy against SP/CD44⁺ tumorigenic cells in Akt/β-catenin-driven hepatocellular carcinoma. J Hepatol. 72:104–118. 2020. View Article : Google Scholar : PubMed/NCBI
24	Wang X, Liao X, Yu T, Gong Y, Zhang L, Huang J, Yang C, Han C, Yu L, Zhu G, et al: Analysis of clinical significance and prospective molecular mechanism of main elements of the JAK/STAT pathway in hepatocellular carcinoma. Int J Oncol. 55:805–822. 2019.PubMed/NCBI
25	Mendez Luque LF, Blackmon AL, Ramanathan G and Fleischman AG: Key role of inflammation in myeloproliferative neoplasms: Instigator of disease initiation, progression, and symptoms. Curr Hematol Malig Rep. 14:145–153. 2019. View Article : Google Scholar : PubMed/NCBI
26	Cornez I, Yajnanarayana SP, Wolf AM and Wolf D: JAK/STAT disruption induces immuno-deficiency: Rationale for the development of JAK inhibitors as immunosuppressive drugs. Mol Cell Endocrinol. 451:88–96. 2017. View Article : Google Scholar : PubMed/NCBI
27	Welsch K, Holstein J, Laurence A and Ghoreschi K: Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors. Eur J Immunol. 47:1096–1107. 2017. View Article : Google Scholar : PubMed/NCBI
28	Fischer M, Quaas M, Steiner L and Engeland K: The p53-p21-DREAM-CDE/CHR pathway regulates G2/M cell cycle genes. Nucleic Acids Res. 44:164–174. 2016. View Article : Google Scholar : PubMed/NCBI